CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ (DEFICIT)/EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Total Microvast Holdings, Inc. shareholders’ (Deficit)/ Equity	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated other comprehensive income/(loss)	Statutory reserve	Noncontrolling interest
Beginning balance (in shares) at Dec. 31, 2020				99,028,297
Beginning balance at Dec. 31, 2020	$ (384,602)			$ 6	$ 0	$ (397,996)		$ 7,356	$ 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(206,483)					(206,483)
Accretion for Series C1 Preferred	(2,257)				0	(2,257)
Accretion for Series C2 Preferred	(5,132)					(5,132)
Accretion for Series D1 Preferred	(10,708)					(10,708)
Accretion for redeemable noncontrolling interests	(5,841)					(5,841)
Accretion for the exiting noncontrolling interests	(3,682)					(3,682)
Issuance of common stock upon the reverse recapitalization, net of issuance costs (in shares)				191,254,950
Issuance of common stock upon the reverse recapitalization, net of issuance costs	1,241,851			$ 23	1,241,828
Issuance of common stock in connection with vesting of restricted stock units and stock options (including the conversion and vesting of Series B2 preferred) (in shares)				8,559,769
Issuance of common stock in connection with vesting of restricted stock units and stock options (including the conversion and vesting of Series B2 preferred)	39,533			$ 1	39,532
Share-based compensation	24,674				24,674
Foreign currency translation adjustments	(655)							(655)
Ending balance (in shares) at Dec. 31, 2021				298,843,016
Ending balance at Dec. 31, 2021	686,698			$ 30	1,306,034	(632,099)		6,701	6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(158,200)					(158,200)
Issuance of common stock in connection with vesting of share-based awards (in shares)				8,785,495
Issuance of common stock in connection with vesting of share-based awards	0			$ 1	(1)
Share-based compensation	110,127				110,127
Foreign currency translation adjustments	(24,782)							(24,782)
Ending balance (in shares) at Dec. 31, 2022				307,628,511
Ending balance at Dec. 31, 2022	612,977	$ (866)	$ 612,977	$ 31	1,416,160	(791,165)	$ (866)	(18,081)	6,032	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(106,412)		(106,336)			(106,336)				(76)
Capital contribution from noncontrolling interests	2,174									2,174
Reduction of noncontrolling interest	(2,174)		(164)		(164)					(2,010)
Issuance of common stock in connection with vesting of restricted stock units and stock options (including the conversion and vesting of Series B2 preferred) (in shares)				7,378,431
Issuance of common stock in connection with vesting of restricted stock units and stock options (including the conversion and vesting of Series B2 preferred)	0			$ 1	(1)
Share-based compensation	65,246		65,246		65,246
Foreign currency translation adjustments	(7,621)		(7,533)					(7,533)		(88)
Ending balance (in shares) at Dec. 31, 2023				315,006,942
Ending balance at Dec. 31, 2023	$ 564,190		$ 564,190	$ 32	$ 1,481,241	$ (897,501)		$ (25,614)	$ 6,032	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2016-13 [Member]